tbuckley/cabot-search huggingface dataset:
CD105 expression in early erythroid precursors
Authors: José Antonio García‐Vela, Isaac Martin Rubio, Juan Marquet, Miguel Angel Alvarez Juarez
Journal: American Journal of Hematology (2017)

We read with interest the article by Wang et al. regarding pure erythroid leukemia (PEL).1 In the immunophenotype and markers section for PEL they consider that ideally a marker for PEL should only highlight proerythroblasts and be negative in more mature erythroid cells and cells of other lineages. The CD105 antigen (endoglobin) has been traditionally used as an endothelial marker.2 Mesenchymals cells also express CD105 in combination with CD13, CD10, HLA-DR, and CD90 without reactivity for CD45 and CD117 markers.3 Using six to eight-colors flow cytometry in different antigens combinations, CD105 can also be used to detect immature erythroid progenitors. Human BFU-E are CD34+, CD45+, Glicophorin A (CD235a)–, CD36– or low, and CD71 low, whereas CFU-E cells are CD34–, CD235a–, CD36+, and CD71++.4 In Figure 1, a subset of CD34 cells (dark green cells) CD117+ shows a progressive expression of CD105 and CD36 and may be considered the CD34+ erythroid progenitors. Proerythroblasts are characterized by their expression of CD117+, CD105++, HLA-Dr–/+, CD36++, CD71+, CD45 –/+ with higher granularity (SSC) than mature erythroid cells. Basophilic erythroblasts also show reactivity for CD105, but they do not have expression of CD117, HLA-Dr, and have a brighter expression of CD36 and CD71 (Figure 1).2, 5 CD105 is not expressed on polychromatophilic, erythroblasts orthochromatophilic, and mature erythroid cells. The combination of CD235a, band3, and α4-integrin may also contribute to the differentiation between proerythroblasts (α4-integrin+ and band3 negative) and basophilic erythroblasts (α4-integrin+, and band3+/−).6 Therefore, CD105 in combination with CD36, CD71, CD117, HLA-DR, CD45, CD34, and CD235a may be considered a immunophenotypic strategy for the detection of erythroid progenitors and early erytrhoid precursors in myelodisplastic syndromes and PEL. Flow cytometric dot plots of normal erythroid differentiation from CD34+ cells in normal bone marrow. A small subset of CD34+ CD117+ cells (dark green dots) shows a progressive expression of CD105 and CD36 (CD34+ erythroid progenitors); proerythroblasts (red dots) are defined as CD34–/CD117+CD36+CD105+/CD71+/CD235a+, and basophilic erythroblasts (green dots) as CD34–CD117–CD36++CD105+CD71+CD235a+. CD105 is negative from polychromatophilic erythroblasts (blue dots) to the end stages of the erythropoiesis. Myeloid progenitors are CD34+CD117+HLA-Dr+CD105– (violet dots). [Color figure can be viewed at wileyonlinelibrary.com] Nothing to report.
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease
Authors: Lisa M. Wilson, Casey M. Rebholz, Ermias Jirru, Marisa Chi Liu, Allen Zhang, Jessica Gayleard, Yue Chu, Karen A. Robinson
Journal: Annals of Internal Medicine (2017)

Complications of chronic kidney disease (CKD) include weak bones and increased fracture risk.To review the benefits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with placebo, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in patients with CKD.PubMed and the Cochrane Central Register of Controlled Trials from December 2006 through December 2016.Paired reviewers independently screened abstracts and full-text articles for English-language, randomized, controlled trials that had at least 6 months of follow-up; evaluated osteoporosis medications among patients with CKD; and reported on BMD, fractures, or safety (mortality and adverse events).Two reviewers serially abstracted data and independently assessed risk of bias and graded the strength of evidence (SOE).There were 13 trials (n = 9850) that included kidney transplant recipients (6 trials), patients who had stage 3 to 5 CKD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials). Evidence showed that bisphosphonates may slow loss of BMD among transplant recipients (moderate SOE), but their effects on fractures and safety in transplant recipients and others with CKD are unclear. Raloxifene may prevent vertebral fractures but may not improve BMD (low SOE). Effects of teriparatide and denosumab on BMD and fractures are unclear (very low SOE), and these medications may increase risk for some safety outcomes.Unclear rigor of evidence, possible reporting biases, and scant evidence among patients with stage 3 to 5 CKD.Effects of osteoporosis medications on BMD, fracture risk, and safety among patients with CKD are not clearly established.Kidney Disease: Improving Global Outcomes.
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic
Authors: Girish S. Kulkarni, Thomas Hermanns, Yanliang Wei, Bimal Bhindi, Raj Satkunasivam, Paul Athanasopoulos, Peter J. Bostrom, Cynthia Kuk, Kathy Li, Arnoud J. Templeton, Srikala S. Sridhar, Theodorus H. van der Kwast, Peter Chung, Robert G. Bristow, Michael Milosevic, Padraig Warde, Neil E. Fleshner, Michael A.S. Jewett, Shaheena Bashir, Alexandre R. Zlotta
Journal: Journal of Clinical Oncology (2017)

Purpose Multidisciplinary management improves complex treatment decision making in cancer care, but its impact for bladder cancer (BC) has not been documented. Although radical cystectomy (RC) currently is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-based, bladder-sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treatment option. In the absence of randomized studies, this study compared the oncologic outcomes between patients treated with RC or TMT by using a propensity score matched-cohort analysis. Methods Data from patients treated in a multidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013 were reviewed retrospectively. Those who received TMT for MIBC were identified and matched (for sex, cT and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score, treatment date, age, carcinoma in situ status, and hydronephrosis) with propensity scores to patients who underwent RC. Overall survival and disease-specific survival (DSS) were assessed with Cox proportional hazards modeling and a competing risk analysis, respectively. Results A total of 112 patients with MIBC were included after matching (56 who had been treated with TMT, and 56 who underwent RC). The median age was 68.0 years, and 29.5% had stage cT3/cT4 disease. At a median follow-up of 4.51 years, there were 20 deaths (35.7%) in the RC group (13 as a result of BC) and 22 deaths (39.3%) in the TMT group (13 as a result of BC). The 5-year DSS rate was 73.2% and 76.6% in the RC and TMT groups, respectively ( P = .49). Salvage cystectomy was performed in 6 (10.7%) of 56 patients who received TMT. Conclusion In the setting of a MDBCC, TMT yielded survival outcomes similar to those of matched patients who underwent RC. Appropriately selected patients with MIBC should be offered the opportunity to discuss various treatment options, including organ-sparing TMT.
Screening for Diabetic Retinopathy
Authors: Jamie B. Rosenberg, Irena Tsui
Journal: New England Journal of Medicine (2017)

Screening tests are performed in asymptomatic persons to assess for the presence of a particular disease or the risk of that disease. An effective screening test should reduce morbidity and mortality in a population by detecting disease at a stage at which treatment will make a difference. However, even when a screening test is considered to be effective, questions remain. At what age should screening begin or end? How frequently should screening be performed?In this issue of the Journal, Nathan et al., reporting for the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications . . .
Perturbation effect of reduced graphene oxide quantum dots (rGOQDs) on aryl hydrocarbon receptor (AhR) pathway in zebrafish
Authors: Jing-Hui Zhang, Tai Sun, Aping Niu, Yu-Mei Tang, Shun Deng, Wei Luo, Qun Xu, Dapeng Wei, De-Sheng Pei
Journal: Biomaterials (2017)
TCTAP C-163 Case Report Simply Describes Lesion Is Not Simple Procedure LAD Vessel Perforating Complication During Wiring in Primary Angioplasty
Authors: Zulfikri Mukhtar, Teuku Bob Haykal, Andika Sitepu, Cut Aryfa Andra, Nizam Zikri Akbar, Sutomo Kasiman, Amran Lubis, Tawanita Brahmana
Journal: Journal of the American College of Cardiology (2017)
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
Authors: Lee M. Krug, Antoinette J. Wozniak, Hedy Lee Kindler, Ronald Feld, Marianna Koczywas, Jose Luis Morero, Cristina P. Rodriguez, Helen J. Ross, Julie E. Bauman, Sergey V Orlov, John C. Ruckdeschel, Alain C. Mita, Luis Fein, Cristian Fernandez, Robert Hall, Takumi Kawabe, Sunil Sharma
Journal: Journal of Clinical Oncology (2012)

7029 Background: CBP501, a synthetic duodecapeptide, enhances the cytotoxicity of cisplatin in cell lines and xenografts, including NCI-H226 human mesothelioma. CBP501 increases cisplatin influx into tumor cells through an interaction with calmodulin, and inhibits cell cycle progression by abrogating DNA repair at the G2 checkpoint. Phase I clinical trials combining CBP501 with cisplatin alone or with pemetrexed showed acceptable safety profiles and suggested activity. The most common toxicity of CBP501 is infusion-related urticaria, which is easily managed with diphenhydramine. Methods: Chemotherapy-naive patients with unresectable MPM were stratified by histology (epithelioid vs other) and performance status (PS 0-1 vs 2) and randomized 2:1 to Arm A: pemetrexed/cisplatin plus CBP501 25 mg/m 2 IV (42 pts planned), or Arm B: pemetrexed/cisplatin alone at standard doses (21 pts planned). Patients continued on treatment until progression or intolerance; no maintenance therapy was delivered. The primary endpoint is progression free survival (PFS) in Arm A; if &gt; 23 of the 42 patients remain free of progression more than 4 months, the combination will be deemed worthy of further study. In addition to standard CT imaging to assess response and PFS, PET scans, pulmonary function tests, and mesothelin levels were performed. Results: Enrollment was completed in October 2011. 65 pts from 14 institutions were randomized, and 63 were treated. Patient characteristics in the two arms were similar and as follows: median age 65, 82% male, 71% epithelioid histology, 8% PS2. Grade 3/4 treatment-related toxicities were uncommon, no different than expected from standard chemotherapy, and comparable in the two arms. 70% of patients treated with CBP501 had infusion reactions, all grade 1-2. The best overall response rate in evaluable patients (modified RECIST, investigator assessed) was 12/37 (32%) (95% CI 18-50) in Arm A, and 3/22 (14%) (95% CI 3-35) in Arm B. The median number of chemotherapy cycles was 5.5 in Arm A, 5 in Arm B. Conclusions: Data on the primary endpoint of PFS in Arm A are maturing and will be presented at the meeting.
Modulation of Heterotypic and Homotypic Cell-Cell Interactions via Zwitterionic Lipid Masks
Authors: Matthew Park, Wongu Youn, Doyeon Kim, Eun Hyea Ko, Beom Jin Kim, Sung Min Kang, Kyungtae Kang, Insung S. Choi
Journal: Advanced Healthcare Materials (2017)

Since the pioneering work by Whitesides, innumerable platforms that aim to spatio‐selectively seed cells and control the degree of cell–cell interactions in vitro have been developed. These methods, however, have generally been technically and methodologically complex, or demanded stringent materials and conditions. In this work, we introduce zwitterionic lipids as patternable, cell‐repellant masks for selectively seeding cells. The lipid masks are easily removed with a routine washing step under physiological conditions (37 °C, pH 7.4), and are used to create patterned cocultures, as well as to conduct cell migration studies. We demonstrate, via patterned cocultures of NIH 3T3 fibroblasts and HeLa cells, that HeLa cells proliferate far more aggressively than NIH 3T3 cells, regardless of initial population sizes. We also show that fibronectin‐coated substrates induce cell movement akin to collective migration in NIH 3T3 fibroblasts, while the cells cultured on unmodified substrates migrate independently. Our lipid mask platform offers a rapid and highly biocompatible means of selectively seeding cells, and acts as a versatile tool for the study of cell–cell interactions.
Eruption of Yellow-Brown and Red-Brown Papules in a Young Adult With Polydipsia and Polyuria
Authors: Jessica M. Donigan, Zachary N. Collins, David A. Wada
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Lower-Segment Caesarean Section
Authors: B. C. Murless
Journal: BMJ (1948)

MEDICALSOHURNAL,~~~~~~~~~~~~~~~~~~~~~~~~~EIA JORA prove sufficient for this purpose.The optimum dosage has not yet been determined, but continuity of treatment is considered essential.When retention or severe obstructive symptoms necessitate a transurethral resection the oppor- tunity is taken of removing the testicular substance and stilboestrol is withheld, to be used as a final measure if signs of reactivity manifest themselves. ConclusionThe following table shows the different methods I have employed in a personal series of 310 consecutive operations for prostatic obstruction during the past two years: Operations for Prostatic Obstruction, December, 1945, to November, 1947 Method of Operation No. Mortality Retropubic prostatectomy .205(7 2-stage) 15 (7-2%) Prostatectomy by Wilson Hey technique 43 3 (6-9%) Suprapubic prostatectomy .10 (92-stage) O (0y) Transurethral resection .41(19 malignant) 1 (2 4%/) Suprapubic cystostomy.11
A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure
Authors: Jeong Hyun Lee, Raiees Andrabi, Ching-Yao Su, Anila Yasmeen, Jean-Philippe Julien, Leopold Kong, Nicholas C. Wu, Ryan McBride, Devin Sok, Matthias Pauthner, Christopher A. Cottrell, Travis Nieusma, Claudia Blattner, James C. Paulson, Per Johan Klasse, Ian A. Wilson, Dennis R. Burton, Andrew B. Ward
Journal: Immunity (2017)

Broadly neutralizing antibodies (bnAbs) to HIV delineate vaccine targets and are prophylactic and therapeutic agents. Some of the most potent bnAbs target a quaternary epitope at the apex of the surface HIV envelope (Env) trimer. Using cryo-electron microscopy, we solved the atomic structure of an apex bnAb, PGT145, in complex with Env. We showed that the long anionic HCDR3 of PGT145 penetrated between glycans at the trimer 3-fold axis, to contact peptide residues from all three Env protomers, and thus explains its highly trimer-specific nature. Somatic hypermutation in the other CDRs of PGT145 were crucially involved in stabilizing the structure of the HCDR3, similar to bovine antibodies, to aid in recognition of a cluster of conserved basic residues hypothesized to facilitate trimer disassembly during viral entry. Overall, the findings exemplify the creative solutions that the human immune system can evolve to recognize a conserved motif buried under a canopy of glycans.
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
Authors: Wendy A. Cooper, Prudence A. Russell, Maya Cherian, Edwina E. Duhig, David Godbolt, Peter J. Jessup, Christine Khoo, Connull Leslie, Annabelle Mahar, David F. Moffat, Vanathi Sivasubramaniam, Celine Faure, Alena Reznichenko, Amanda Grattan, Stephen B. Fox
Journal: Clinical Cancer Research (2017)

Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are necessary to identify responders to anti-PD-1 therapy. We tested the reproducibility of the assessment of PD-L1 expression in non-small cell lung cancer (NSCLC) tissue samples by pathologists.Experimental Design: NSCLC samples were stained with PD-L1 22C3 pharmDx kit using the Dako Autostainer Link 48 Platform. Two sample sets of 60 samples each were designed to assess inter- and intraobserver reproducibility considering two cut points for positivity: 1% or 50% of PD-L1 stained tumor cells. A randomization process was used to obtain equal distribution of PD-L1 positive and negative samples within each sample set. Ten pathologists were randomly assigned to two subgroups. Subgroup 1 analyzed all samples on two consecutive days. Subgroup 2 performed the same assessments, except they received a 1-hour training session prior to the second assessment.Results: For intraobserver reproducibility, the overall percent agreement (OPA) was 89.7% [95% confidence interval (CI), 85.7-92.6] for the 1% cut point and 91.3% (95% CI, 87.6-94.0) for the 50% cut point. For interobserver reproducibility, OPA was 84.2% (95% CI, 82.8-85.5) for the 1% cut point and 81.9% (95% CI, 80.4-83.3) for the 50% cut point, and Cohen's κ coefficients were 0.68 (95% CI, 0.65-0.71) and 0.58 (95% CI, 0.55-0.62), respectively. The training was found to have no or very little impact on intra- or interobserver reproducibility.Conclusions: Pathologists reported good reproducibility at both 1% and 50% cut points. More adapted training could potentially increase reliability, in particular for samples with PD-L1 proportion, scores around 50%. Clin Cancer Res; 23(16); 4569-77. ©2017 AACR.
NHS may turn to private sources for cash boost
Authors: Adrian O’Dowd
Journal: BMJ (2017)

NHS Improvement, the NHS financial watchdog, is considering borrowing billions of pounds from private investment companies to help pay for health service infrastructure. Some have questioned the idea, however, as it may place an unfair burden on future generations.

NHS Improvement has confirmed that the issue was discussed during a regular meeting on 10 April between the agency’s chief executive, Jim Mackey, and the Treasury, which would have to approve such a move.

Mackey, interviewed in the Times newspaper on 9 April, discussed his plans to get Treasury approval for deals already discussed with hedge funds and other private investment companies. Money from such a source could help create a central NHS infrastructure fund to which …
Thresholds for Ambulatory Blood Pressure Among African Americans in the Jackson Heart Study
Authors: Joseph Ravenell, Daichi Shimbo, John N. Booth, Daniel F. Sarpong, Charles Agyemang, Danielle L. Beatty Moody, Marwah Abdalla, Tanya M. Spruill, Amanda J. Shallcross, Adam P. Bress, Paul Muntner, Gbenga Ogedegbe
Journal: Circulation (2017)

Ambulatory blood pressure (BP) monitoring is the reference standard for out-of-clinic BP measurement. Thresholds for identifying ambulatory hypertension (daytime systolic BP [SBP]/diastolic BP [DBP] ≥135/85 mm Hg, 24-hour SBP/DBP ≥130/80 mm Hg, and nighttime SBP/DBP ≥120/70 mm Hg) have been derived from European, Asian, and South American populations. We determined BP thresholds for ambulatory hypertension in a US population-based sample of African American adults.
Evaluating quality in endoscopy
Authors: Heiko Pohl
Journal: Endoscopy (2017)

Abstract Despite an increasing number of publications and suggested quality measures, evaluating quality in endoscopy remains a challenge. Most quality measures are process measures and lack evidence for an association with clinically important outcomes. Furthermore, most measure focus on procedural aspects. Patients’ expectations, cultural values, and work setting also affect quality, but are less often considered. The aim of this article is to broaden the view on quality assessment. Here, quality is viewed from four perspectives: an individual patient perspective, which considers expectations and personal values; a cultural perspective, which encompasses cultural values and norms; an individual care perspective, which includes how an individual patient is being treated; and a societal perspective, which sets the stage for provided care. The article concludes with a proposal to consider bundled composite measures as a path to a simple yet comprehensive approach to assessing and measuring quality in endoscopy.
Cyclosporin A, a P-gp Inhibitor, Augments the Anti-Central Nervous System Ph+ Leukemia Effects of INNO-406.
Authors: Asumi Yokota, Shinya Kimura, Satohiro Masuda, Eishi Ashihara, Yoshimasa Urasaki, Yasuhito Terui, Martin Ruthardt, Takanori Ueda, Kiyohiko Hatake, Ken-ichi Inui, Taira Maekawa
Journal: Blood (2006)
Anticoagulation Reversal for Supratherapeutic International Normalized Ratio
Authors: Sri Lekha Tummalapalli, Yue Qiu, Hyung J. Cho
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal